Meanwhile, the IC50 concentration of cisplatin for cancer cells reduced dramatically from 5.8 μg/mL in control cells to 2.27 μg/mL in SLPI siRNA-transfected cells, demonstrating that siSLPI enhances the CRC chemosensitivity to Cisplatin treatment. The gene discussed is SLPI; the disease is cancer.